Cyberonics’ VNS Depression Indication Delayed Two Years By Trial Results
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics does not expect its annual losses to grow over the next three years due to the failure of a pivotal trial to demonstrate the efficacy of the NeuroCybernetic Prosthesis (NCP) vagus nerve stimulation (VNS) system in treating depression